ANI Pharmaceuticals' GAAP loss for 2021 was $42.603 million, up 88.9% from $22.548 million in the prior year. Revenue increased 3.7% to $216.136 million from $208.475 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept